重症患者中penKid定义的亚临床急性肾损伤发生率与结局
本研究为两项ICU前瞻性观察队列的辅助分析,FROG-ICU纳入2087例重症患者、AdrenOSS-1纳入583例脓毒症患者,以入院penKid>80 pmol/L且不符合AKI定义判定亚临床AKI。FROG-ICU中6.1%(122/2004)、AdrenOSS-1中6.7%(39/583)符合亚临床AKI,分别占无AKI患者的11.6%和17.5%。校正年龄、性别、合并症、诊断、肌酐、尿量及研究后,无AKI患者中penKid与更高死亡率相关(校正标准化HR 1.4,95%CI 1.1–1.8,P=0.010);eGFR>60 ml/min/1.73 m²者中HR 1.6(95%CI 1.3–1.8,P<0.0001)。亚临床AKI患者死亡风险高于无AKI者(FROG-ICU HR 2.4,95%CI 1.5–3.7;AdrenOSS-1 HR 2.5,95%CI 1.1–5.9)。
要点
- 亚临床AKI定义为入院penKid>80 pmol/L且不符合AKI定义,在无AKI重症患者中占11.6%–17.5%。
- 无AKI患者中penKid升高与28天死亡风险独立相关:校正标准化HR 1.4(95%CI 1.1–1.8,P=0.010)。
- eGFR>60 ml/min/1.73 m²的患者中,penKid与死亡风险相关HR 1.6(95%CI 1.3–1.8,P<0.0001)。
- 亚临床AKI患者28天死亡风险高于无AKI者:FROG-ICU HR 2.4(95%CI 1.5–3.7),AdrenOSS-1 HR 2.5(95%CI 1.1–5.9)。
- penKid可在肌酐尚正常时提示肾小球功能受损,识别常规标准漏诊的高死亡风险患者。
适用人群与场景
- FROG-ICU队列:ICU收治的2087例重症患者,来自法国及欧洲多中心。
- AdrenOSS-1队列:583例严重脓毒症和脓毒性休克患者。
- 亚临床AKI分析人群:不符合AKI定义且入院penKid>80 pmol/L的患者;敏感性分析人群为入院eGFR>60 ml/min/1.73 m²者。
诊断标准与关键阈值
- 亚临床AKI:入院penKid浓度高于正常范围(即>80 pmol/L)且不符合AKI定义。
- 敏感性分析采用入院eGFR>60 ml/min/1.73 m²作为入组条件。
研究设计与关键结果
- 研究类型:两项ICU前瞻性观察队列(FROG-ICU和AdrenOSS-1)的辅助研究;FROG-ICU纳入2087例重症患者,AdrenOSS-1纳入583例脓毒症患者。
- 主要终点为ICU入院后28天死亡率。
- FROG-ICU中6.1%(122/2004)符合亚临床AKI定义,占无AKI患者的11.6%;AdrenOSS-1中6.7%(39/583)符合,占无AKI患者的17.5%。
- 无AKI患者中,校正年龄、性别、合并症、诊断、肌酐、尿量及研究后,penKid与更高死亡率相关:校正标准化HR 1.4(95%CI 1.1–1.8,P=0.010)。
- eGFR>60 ml/min/1.73 m²的患者中,校正后penKid与更高死亡率相关:HR 1.6(95%CI 1.3–1.8,P<0.0001)。
- 亚临床AKI患者死亡风险高于无AKI者:FROG-ICU HR 2.4(95%CI 1.5–3.7),AdrenOSS-1 HR 2.5(95%CI 1.1–5.9)。
证据类型、等级与局限
- 证据类型:两项前瞻性观察队列的辅助研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于肌酐正常、不符合AKI标准的重症患者,入院penKid>80 pmol/L提示亚临床AKI,其28天死亡风险接近AKI患者(FROG-ICU HR 2.4,AdrenOSS-1 HR 2.5)。
- 在eGFR>60 ml/min/1.73 m²的患者中,penKid升高仍与更高死亡风险相关(HR 1.6,95%CI 1.3–1.8),提示肾功能指标正常时也应关注penKid。
- 该研究为观察性辅助分析,penKid检测是否改变临床处置尚未在干预性研究中验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Subclinical acute kidney injury (sub-AKI) refers to patients with low serum creatinine but elevated alternative biomarkers of AKI. Its incidence and outcome in critically ill patients remain, however, largely unknown. Plasma proenkephalin A 119-159 (penKid) has been proposed as a sensitive biomarker of glomerular function.Objectives: In this ancillary study of two cohorts, we explored the incidence and outcome of sub-AKI based on penKid.Methods: A prospective observational study in ICUs was conducted. FROG-ICU (French and European Outcome Registry in ICUs) enrolled 2,087 critically ill patients, and AdrenOSS-1 (Adrenomedullin and Outcome in Severe Sepsis and Septic Shock-1) enrolled 583 septic patients. The primary endpoint was 28-day mortality after ICU admission. Sub-AKI was defined by an admission penKid concentration above the normal range (i.e., >80 pmol/L) in patients not meeting the definition of AKI. A sensitivity analysis was performed among patients with estimated glomerular filtration rate above 60 ml/min/1.73 m2 at ICU admission.Measurements and Main Results: In total, 6.1% (122/2,004) and 6.7% (39/583) of patients from the FROG-ICU and AdrenOSS-1 cohorts met the definition of sub-AKI (11.6% and 17.5% of patients without AKI). In patients without AKI or with high estimated glomerular filtration rate, penKid was associated with higher mortality (adjusted standardized hazard ratio [HR], 1.4 [95% confidence interval, 1.1-1.8]; P = 0.010; and HR, 1.6 [95% confidence interval, 1.3-1.8]; P < 0.0001, respectively) after adjustment for age, sex, comorbidities, diagnosis, creatinine, diuresis, and study. Patients with sub-AKI had higher mortality compared with no AKI (HR, 2.4 [95% confidence interval, 1.5-3.7] in FROG-ICU and 2.5 [95% confidence interval, 1.1-5.9] in AdrenOSS-1).Conclusions: Sub-AKI defined using penKid occurred in 11.6-17.5% of patients without AKI and was associated with a risk of death close to patients with AKI.
参考来源
- Dépret F, Hollinger A, Cariou A, et al. Incidence and Outcome of Subclinical Acute Kidney Injury Using penKid in Critically Ill Patients. Am J Respir Crit Care Med. 2020. PMID: 32516543. doi:10.1164/rccm.201910-1950OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。